| 영문 | rheumatoid factor | 한글 | 류마티스 인자 |
|---|---|---|---|
| 설명 | IgG의 Fc부위에 있는 항원결정인자에 대한 항체로서 전형적인 또는 확실한 류마티스관절염(rheumatoid arthritis) 환자의 80%에서 발견된다. 류마티스 인자는 IgM, IgG, IgA중 하나가 될 수 있으나 주로 IgM이다. 소아류마티스관절염(juvenile rheumatoid arthritis: 소아기에 발생하는 류마티스관절염)을 비롯한, 다른 결합조직병이나 감염병에도 나타날 수 있다 |
||
| 영문 | growth factor | 한글 | 성장인자 |
|---|---|---|---|
| 설명 | 세포의 분화 및 성장에 관여하는 단백질. 성장인자는 정상 세포주기에 필수적이기 때문에 동물의 생명에 중대한 요소가 된다. 무엇보다도 성장인자는 태아의 발육을 조정하고 조직의 유지 및 보수에 중대한 역할을 하며, 혈구의 생성을 자극한다. 또한 암의 진행과정에도 관여한다. |
||
| 영문 | risk factor | 한글 | 위험인자 |
|---|---|---|---|
| 설명 | 국제방사선방호위원회(ICRP)가 1977년 권고에서 방사선방호의 목적으로 채택한 지수로, 단위선량(1 Sv)당 확률적 영향의 발생확률을 추정하여 나타낸 것이다. 생식선 선량에 대한 유전적영향의 발생률(4×10－3/Sv)이나 적색골수선량에 대한 백혈병 발생률(2×10－3/Sv)등 외에 뼈, 허파, 갑상샘, 젖샘, 기타 조직의 위험지수를 측정하여, 확률적 영향의 전신에 있어서 치사위험지수의 합계를 16.5×10－3/Sv로 하였다. 그후 ICRP는 1990년 권고에서 대상이 되는 조직과 장기를 추가하고, 수치 개정을 하면서 명칭도 각목적확률지수라고하였다. 이 권고에 의하면, 치사적 확률적 영향의 확률지수의 합계는, 일반인에 있어 60.0×10－3/Sv이다. |
||
| CF | calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ... |
|---|---|
| BMPI | bronchial mucous proteinase inhibitor |
| CPI | California Personality Inventory; Cancer Potential Index; congenital palatopharyngeal incompetence; ... |
| LIF | laser-induced fluorescence; left iliac fossa; left index finger; leukemia-inhibiting factor; leukocy... |
| BPTI | basic pancreatic trypsin inhibitor; basic polyvalent trypsin inhibitor; bovine pancreatic trypsin in... |
| CPI | 1-cysteine proteinase inhibitor |
|---|---|
| PI | 1-proteinase inhibitor |
| ACPI | Acid cysteine proteinase inhibitor |
| alpha 1-PI | Alpha 1-proteinase inhibitor |
| A1-Pi | Alpha-1 proteinase inhibitor |
IGF-II : insulin like growth factor-II의 약자. 많은 장기와 조직에 작용하여 단백 합성과 DNA, RNA의 합성을 증가시켜 세포의 수와 양을 증가
| proteinase inhibitor inducing factor | See: PIIF. (18 Nov 1997) |
|---|
| resistance-inducing factor | An agent from normal chick embryos that interferes with multiplication of the avian leukosis-sarcoma virus, and is seemingly an avirulent leukosis virus antigenically related to the avian leukosis-sarcoma virus. (05 Mar 2000) |
|---|---|
| human a1-proteinase inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| menstruation-inducing agents | Chemical compounds that induce menstruation either through direct action on the reproductive organs or through indirect action by relieving another condition of which amenorrhoea is a secondary result. (12 Dec 1998) |
| mink cell focus-inducing viruses | Murine leukaemia viruses discovered in 1976 by hartley, wolford, old, and rowe and so named because the viruses originally isolated had the capacity to transform cell foci in mink cell cultures. Mcf viruses are generated in a multi-step process by recombination with other viral types including akr, friend, moloney, and rauscher. (12 Dec 1998) |
| delta sleep-inducing peptide | <chemical> A nonapeptide that is found in neurons, peripheral organs, and plasma. This neuropeptide induces mainly delta sleep in mammals. In addition to sleep, the peptide has been observed to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal. Chemical name: Delta sleep-inducing peptide (12 Dec 1998) |
| a1-trypsin inhibitor | A glycoprotein that is the major protease inhibitor of human serum, is synthesised in the liver, and is genetically polymorphic due to the presence of over 20 alleles; individuals appropriately homozygous are deficient in a1-trypsin and are predisposed to pulmonary emphysema and juvenile hepatic cirrhosis because of alterations in the amino acid and sialic acid components of the glycoprotein. A1-Antitrypsin also inhibits thrombin. Synonym: a1-trypsin inhibitor, human a1-proteinase inhibitor. (05 Mar 2000) |
| ACE inhibitor | <pharmacology> A group of antihypertensive medications that work by inhibiting an enzyme (angiotensin-converting enzyme) that is important in the regulation of blood pressure. Studies have also indicated that it may help prevent or slow the progression of kidney disease in patients with diabetes. Examples include: captopril, ramipril, enalapril, losartan potassium, bepridil and lisinopril. (12 Mar 1998) |
| aldose reductase inhibitor | <pharmacology> A class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes. Aldose reductase is an enzyme that is normally present in the eye and in many other parts of the body. It helps change glucose (sugar) into a sugar alcohol called sorbitol. Too much sorbitol trapped in eye and nerve cells can damage these cells, leading to retinopathy and neuropathy. Drugs that prevent or slow (inhibit) the action of aldose reductase are being studied as a way to prevent or delay these complications of diabetes. (09 Oct 1997) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
| aromatase inhibitor | Drugs, such as aminoglutethimide, that inhibit aromatase, an enzyme used in the synthesis of oestrogens. (05 Mar 2000) |
| beta-lactamase inhibitor | <pharmacology> Drugs such as clavulanic acid, which are used to inhibit bacterial beta-lactamases; often used with a penicillin or cephalosporin to overcome drug resistance. (05 Mar 2000) |
| Bowman-Birk inhibitor | A polypeptide that will inhibit both trypsin and chymotrypsin. (05 Mar 2000) |
| C1 esterase inhibitor | An a2-neuraminoglycoprotein that inhibits the enzymatic activity of C1 esterase, the activated first component of complement. A deficiency of this inhibitor results in a lack of inhibition of C1r and C1s leading to uncontrolled activation of the complement cascade and oedema. (05 Mar 2000) |
| carbonate dehydratase inhibitor | An agent, usually chemically related to the sulfonamides, that inhibits the activity of carbonate dehydratase, producing a general decrease in the formation of H2CO3 in the tissues. See: acetazolamide, dichlorphenamide. Synonym: carbonic anhydrase inhibitor. (05 Mar 2000) |
| carbonic acid inhibitor | <pharmacology> A group of diuretic medications which act to inhibit the enzyme carbonic anhydrase to create a metabolic acidosis. Many of these medications are used in the treatment of glaucoma. (27 Sep 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|